HealthManagement, Volume 2 - Issue 2, Winter 2008
Tracleer®, a dual endothelin receptor antagonist has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (WHO FC II). A clinical study of patients with mildly symptomatic WHO FC II led to approval and revealed that even patients with mild symptoms are at risk of rapid deterioration. Tracleer delays disease progression in these patients and Actelion communicates these findings to encourage early diagnosis and intervention.
